As of July 28, 2010, VaxGen Inc. was acquired by diaDexus, Inc., in a reverse merger transaction. VaxGen, Inc. does not have significant operations. The company seeks to enter into a strategic transaction or series of strategic transactions. Previously, it was engaged in the development of vaccines that immunize against infectious disease. diaDexus, Inc., a life sciences company, focuses on the development and commercialization of proprietary cardiovascular diagnostic products addressing needs in cardiovascular disease. The company?s PLAC Tests, which are provide information to help identify individuals at risk of suffering a heart attack or stroke. It offers PLAC ELISA Test, an aid in predicting risk for coronary heart disease and ischemic strokes associated with atherosclerosis; and PLAC Activity Test, an indicator of atherosclerotic cardiovascular disease. The company markets and distributes its products directly through a sales force to various national and regional clinical reference laboratories in the United States; and through distributors in Europe.
